By Richard Insel, M.D. As JDRF remains steadfast in its mission of curing type 1 diabetes, we are also committed to both improving treatments for individuals with the disease and preventing the disorder itself. Our treatment priorities include developing new drugs and devices that significantly improve glucose control, reduce the daily burden of living with […]
Alpha-to-beta cell conversion or “reprogramming” is an early, but promising, therapeutic strategy for T1D. Scientists have now shown that the body can function normally without most of its alpha cells, addressing a potential safety concern for alpha-to-beta cell conversion.
Question: I have a four-year-old who was diagnosed just last week with type 1 diabetes. I am struggling with whether to put him back into preschool (and if so, when). We are continually adjusting his insulin and he’s experiencing many highs and lows. The preschool is willing to learn about his disease, but with his […]
Q: What is diabetic retinopathy? A: Diabetic retinopathy is the most common diabetic eye disease and a leading cause of blindness in American adults. Diabetic retinopathy is a progressive disease that destroys small blood vessels in the retina, eventually causing vision problems. In its most advanced form–proliferative retinopathy–it can cause blindness. According to the National […]
Congress passed the Special Diabetes Program (SDP) in December 2010, committing $150 million per year to extend the program for an additional two years. The legislation marks the fifth time since 1997 that Congress has supported SDP, underscoring the government’s commitment to accelerating the search for a cure and the development of new treatments for […]
By Kathryn Larson I still wonder, “What was I thinking?” I had spent my entire life in a secure community near Denver, yet when I was presented with the opportunity to take a two-week tour of Vietnam, I jumped at it – in spite of the fact that not only was I new to travel, […]
JDRF and Amylin are enthusiastic about the potential of metreleptin to help improve blood glucose control in people with type 1 diabetes. A successful outcome in the metreleptin study would likely lead to studies with larger numbers of people and the development of alternative treatments to using medical insulin alone.
A simple insulin-infusion warming device, called the InsuPatch, accelerates insulin delivery into the bloodstream by as much as 35 minutes. Speeding up the delivery and action of insulin and reducing the amount of time patients spend in a hyperglycemic state potentially reduces the risk of complications that result from the disease.